OCX

Oncocyte's Participation in Conference: Oncocyte Corp. will be represented by CEO Josh Riggs and CFO Andrea James at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025, where they will discuss the company's innovative diagnostic technologies and progress on a regulated organ transplant rejection monitoring test kit.

Company Overview and Products: Oncocyte specializes in diagnostics technology, offering tests like VitaGraft™ for organ transplantation monitoring and DetermaIO™ for assessing tumor responses to immunotherapies, aiming to enhance clarity and confidence for physicians and patients.

Analyst Coverage and Price Forecast: Lake Street initiated coverage of OncoCyte with a Buy recommendation, projecting a 30.67% upside in the stock price, with an average target of $4.21/share based on recent performance.

Institutional Ownership Changes: There has been a notable increase in institutional ownership of OncoCyte, with several funds increasing their stakes, while AWM Investment reduced its holdings significantly.

OncoCyte's Growth Potential: Lake Street Capital Markets has initiated coverage of OncoCyte with a buy rating, highlighting the company's opportunity for growth in transplant rejection testing using its VitaGraft Plus test, which aims to streamline testing processes for transplant centers.

Future Developments and Projections: The company plans to submit an application for FDA approval of VitaGraft Plus this year, with expectations for marketing by 2026, while targeting $20 million in recurring revenue from 20 transplant centers by 2025.

Upcoming Earnings Reports: Major companies expected to report earnings after the bell on Monday include ABIVAX, KB Home, OncoCyte Corporation, and Oklo.

Earnings Season Calendar: For a complete calendar of the earnings season, readers are directed to Seeking Alpha's full listing.

Earnings Announcement: OncoCyte is set to release its fiscal year earnings results on March 24th, with an expected EPS of -$0.40 and revenue estimates of $0.5M, reflecting a 66.7% decrease year-over-year.

Equity Offering: The company has recently priced a $29.1 million equity offering as part of its financial strategy.

Earnings Reports Overview: The upcoming earnings week will feature reports from various sectors, including retail (Lululemon, Chewy, GameStop), solar energy (Canadian Solar, JinkoSolar), and infrastructure (Argan), with analysts closely monitoring spending trends and financial performance.

Analyst Expectations: Analysts predict mixed outcomes for these companies, with concerns about GameStop's declining sales and KB Home's profit outlook, while Chewy and Lululemon are expected to show growth despite valuation concerns.

Financial Results Announcement: Oncocyte Corp. will report its fourth quarter 2024 financial results on March 24, 2025, and will host a live Zoom webinar at 2:00 p.m. PT to discuss these results.

Company Overview: Oncocyte is a diagnostics technology company specializing in tests for organ transplantation monitoring and cancer treatment efficacy, including products like VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™.

Insider Trading Activity: Andrea S. James, CFO of $OCX, purchased 97,561 shares for approximately $200,000, increasing her holdings by 181.8%, while all 19 insider trades in the past six months have been purchases with no sales reported.

Institutional Investor Movements: In the latest quarter, four institutional investors increased their positions in $OCX stock, while eleven reduced theirs, indicating mixed sentiment among larger shareholders.

Oncocyte's Conference Attendance: Oncocyte Corp. will be represented by CEO Josh Riggs and CFO Andrea James at BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah on February 11-12, 2025, where they will hold one-on-one meetings with investors.

Company Overview: Oncocyte is a leading diagnostics technology company known for its innovative tests like VitaGraft™ and DetermaIO™, aimed at enhancing patient care in solid organ transplantation and cancer treatment.

Oncocyte's Funding Round: Oncocyte has secured $29.1 million through a registered direct offering and private placement led by its largest shareholders, including Bio-Rad Laboratories, with shares priced at $2.05 each.

Strategic Partnership and Future Plans: Bio-Rad will provide financial support for Oncocyte's upcoming clinical trial, enhancing their strategic partnership, while the funding is expected to fully support the development of Oncocyte’s FDA In-Vitro Diagnostic transplant assay program.

Appointment of Dr. Paul Billings: Oncocyte Corp. has appointed Dr. Paul Billings as Consulting Chief Medical Officer to support strategic and clinical goals, leveraging his extensive experience in genomics and precision medicine.

Company Overview and Goals: Oncocyte is a diagnostics technology company focused on developing tests that enhance patient care, with products aimed at organ transplantation monitoring and cancer treatment efficacy.

Appointment Announcement: Oncocyte has appointed Paul Billings as its consulting chief medical officer in a part-time role to assist with strategic and clinical objectives.

Company Overview: The news also references OncoCyte Corporation's Q3 2024 earnings call and mentions Seeking Alpha’s Quant Rating on the company.

Medicare Coverage Expansion: Medicare has expanded coverage for Oncocyte's VitaGraft Kidney test, which detects antibody-mediated rejection (AMR) in kidney transplant patients with newly developed donor-specific antibodies (dnDSA+), allowing for earlier diagnosis and management without invasive procedures.

Clinical Significance: The test can identify AMR up to 11 months earlier than current methods, addressing a critical need as approximately 20% of kidney transplant patients develop dnDSA within five years, significantly impacting graft survival rates.

Insider Trading Activity: Patrick W. Smith, a 10% owner of $OCX, purchased 90,219 shares on December 26, 2024, increasing his holdings by approximately 5.4%, bringing his total to 1,773,903 shares. In the past six months, all insider trades for $OCX have been purchases, with no sales reported.

Institutional Investor Movements: Five institutional investors have recently added shares of $OCX to their portfolios, while 14 have decreased their positions in the last quarter.

Insider Trading Activity: Andrew Arno, a director at $OCX, purchased 12,500 shares on December 26, 2024, increasing his holdings by approximately 18.1%, bringing his total to 81,554 shares. In the past six months, all five insider trades reported were purchases.

Institutional Investor Movements: Recently, five institutional investors increased their positions in $OCX stock while 14 reduced theirs in the last quarter, indicating mixed sentiment among institutional stakeholders.

Oncocyte's Participation in J.P. Morgan Week: Oncocyte Corp. will be represented by CEO Josh Riggs and CFO Andrea James at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025, where they will hold one-on-one meetings with investors.

Company Overview and Products: Oncocyte is a diagnostics technology company focused on tests that enhance clarity for physicians and patients, including blood-based monitoring tools for organ transplantation and cancer treatment efficacy.

DetermaCNI Assay Development: Oncocyte Corp. announced promising results for its DetermaCNI™ assay, a liquid biopsy method that detects somatic copy number aberrations in cerebrospinal fluid, potentially improving the diagnosis and monitoring of central nervous system tumors.

Market Potential and Future Plans: The study highlights a significant market opportunity for DetermaCNI, with nearly 300,000 patients diagnosed with brain tumors annually in the U.S., while Oncocyte aims to commercialize its oncology assays within the next two years.

Oncocyte's Breakthrough in Transplant Monitoring: Oncocyte Corp. has published a study demonstrating that its dd-cfDNA assay, VitaGraft™, can significantly reduce the time to diagnose antibody-mediated rejection (AMR) in kidney transplant patients, identifying issues nearly a year earlier than standard methods.

Implications for Patient Outcomes: The study highlights the potential of early detection and intervention in improving outcomes for high-risk transplant patients, especially as new therapeutic options emerge for managing AMR, thereby enhancing the overall efficacy of transplant care.

Upcoming Financial Results Announcement: Oncocyte Corp will release its third quarter 2024 financial results on November 12, 2024, after U.S. market closes, followed by a conference call at 2:00 p.m. PT to discuss the results.

Company Overview and Products: Oncocyte is a diagnostics technology company offering tests like VitaGraft™ and DetermaIO™, aimed at improving clarity for physicians and patients in organ transplantation and cancer treatment.

Oncocyte Presentation at LD Micro Event: Oncocyte Corp's CEO Josh Riggs will present at the 17th annual LD Micro Main Event on October 29, 2024, in Los Angeles, with opportunities for one-on-one investor meetings.

Event Details: The LD Micro Main Event XVII will take place from October 28 to 30, featuring around 150 companies presenting and engaging in private meetings with investors at the Luxe Sunset Boulevard Hotel.